Physician profile
Yating Wang
NPI 1932760162
$2,596.16
in general payments reported to CMS, 2019-2025
15 companies · $613 in 2025
The $613 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2022: $216 · 2023: $507 · 2024: $982 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.47 |
| Education | $288.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $691.20 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $581.80 | 2022-2024 | Opdivo, Onureg |
| Okami Medical, INC. | $251.07 | 2024-2025 | Lobo |
| Gilead Sciences, INC. | $250.74 | 2023-2024 | Trodelvy |
| Allergan, INC. | $137.70 | 2019 | |
| Seagen INC. | $108.43 | 2023 | Adcetris |
| Kite Pharma, INC. | $107.10 | 2022 | |
| Ucb, INC. | $102.40 | 2019 | |
| Sobi, INC | $99.95 | 2024 | |
| Abbvie INC. | $99.00 | 2025 | |
| Janssen Biotech, INC. | $89.99 | 2024 | Rybrevant |
| Abbott Laboratories | $26.07 | 2019 | |
| Tersera Therapeutics LLC | $20.51 | 2025 | Zoladex |
| Beone Medicines USA, INC. | $18.52 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals Lp | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yating Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.